Croda Denmark is the successor organisation of Brenntag Biosector (Biosector) following their acquisition in 2019. The site at Frederikssund, Denmark, includes R&D, engineering, production QA/QC, administration, warehouse and distribution.
For more than 80 years, Croda Denmark, has been dedicated to safe and effective adjuvants suitable for use in both human and veterinary vaccines with a product portfolio comprising of innovative aluminium- and saponin-based adjuvants. Our manufacturing facility in Frederikssund, Denmark is of the highest quality standards, running the only aseptic and GMP manufacturing site for vaccine adjuvants globally.
Our focus has been to successfully develop, manufacture and market high-quality adjuvants for our pharmaceutical customers. Our industry-leading, Alhydrogel®, Adju-Phos® and Quil-A® are widely recognised in the vaccine industry for their unmatched track record when it comes to a proven history of safe and effective use.
We offer you:
- Industry experience as a world leading adjuvant specialist for vaccines serving the major human and veterinary vaccine producers globally
- Industry leading R&T capabilities resulting in a strong pipeline of innovative, next generation vaccine adjuvants
- Highest quality standards running the only aseptic and GMP certified manufacturing site for adjuvants globally
No other company can match our expertise in adjuvants, which is founded on an unprecedented 80-year heritage in the industry. Our focus today remains as it has always: we are dedicated to innovation and consistency in the quality of the products we supply to our customers.
The combination of a passionate team, strong adjuvant expertise, industry-leading aseptic production facilities and our own dedicated global sales network who is committed to understanding our customers’ needs, will allow our vaccine adjuvant business better penetration into the pharmaceutical market to enhance vaccine development through our classic portfolio as well as through our rich development pipeline. Our commitment to the highest quality standards is a priority for us and our employees are continuously developing and manufacturing the highest quality of adjuvants in the business. We all realise that the vaccines and blood products of tomorrow require new and innovative adjuvants. Our R&D department continuously dedicates their focus on innovation and working hard on the development of the next generation of adjuvants.